Abstract: Novel aromatic ring derivatives represented by formula (I) or their pharmaceutical acceptable salts are provided. wherein Nu represents a 5- or 6-membered aromatic ring; ch1 and ch2 each represents a cross-linking group; and A represents an aromatic ring. These compounds have blood sugar-depressing activity or PDE 5 inhibitory activity and are useful as medicines for treating impaired glucose tolerance, diabetes, diabetic complications, syndrome of insulin-resistance, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular disorders, hyperglycemia, hypertension, stenocardia, pulmonary hypertension, congestive heart failure, glomerulopathy, tubulointerstitial disorders, renal failure, angiostenosis, distal angiopathy, cerebral apoplexy, chronic reversible obstructions, autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by enteromotility disorders, impotence, nephritis, cachexia, pancreatitis, restenosis after PTCA, etc.

Abstract: This invention relates to a heterocyclic compound of the formula wherein a group of the formula: is a group of the formula X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: The invention relates to a pharmaceutical composition for ophthalmic administration comprising a compound of the formula: wherein X1, X2, X3, R1, R2, R3, R4, R5, Q and A are as defined in the disclosure. This invention also relates to methods of using the pharmaceutical composition in the prevention and/or treatment of bradykinin or its analogues mediated diseases in the eye, such as allergy, inflammation and pain of the eye.

Abstract: This invention relates to compounds of formula: ##STR1## wherein R.sup.6, R.sup.7, R.sup.2, R.sup.2, R.sup.3 and A.sup.1 are as defined in the disclosure; and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.

Abstract: This invention relates to a compound of the formula: ##STR1## wherein A.sup.1 is lower alkylene,R.sup.1 is substituted quinolyl, etc.,R.sup.2 is hydrogen, halogen or lower alkyl,R.sup.3 is halogen or lower alkyl, andR.sup.4 is a group of the formula:--Q--A.sup.2 --R.sup.5, etc.,in whichR.sup.5 is amino, acylamino, etc.,A.sup.2 is lower alkylene or a single bond, andQ is a group of the formula: ##STR2## etc., and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: This invention relates to a heterocyclic compound of the formula: ##STR1## wherein a group of the formula: ##STR2## is a group of the formula: ##STR3## etc., X is O, S or N--R.sup.5,R.sup.1 is lower alkyl, etc.,R.sup.5 is hydrogen, lower alkyl, etc.,R.sup.2 is hydrogen, halogen, lower alkyl, etc.,R.sup.3 is halogen, lower alkyl, etc.,R.sup.4 is amino optionally having suitable substituent(s), andA is lower alkylene,and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl,R.sup.2 is hydrogen, lower alkyl or a heterocyclic group,R.sup.3 is hydrogen, lower alkyl or halogen,R.sup.4 is lower alkyl or halogen,R.sup.5 is nitro or amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, andA is lower alkylene.

Abstract: This invention relates to a compound of formula (1) wherein R.sup.1 is halogen, etc., R.sup.2 is halogen, etc., R.sup.3 is amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, etc., R.sup.4 is heterocyclic (lower)alkyl, R.sup.5 is lower alkyl, and A.sup.1 is lower alkylene, and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.

Abstract: This invention relates to a compound of formula (I) wherein A.sup.1 is lower alkylene, R.sup.1 is substituted quinolyl, etc., R.sup.2 is hydrogen, halogen or lower alkyl, R.sup.3 is halogen or lower alkyl, and R.sup.4 is a group of the formula: -Q-A.sup.2 -R.sup.5, etc., in which R.sup.5 is amino, acylamino, etc., A.sup.2 is lower alkylene or a single bond, and Q is a group of formula (a), and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: This invention relates to a compound of the formula: ##STR1## wherein Z is a group of the formula: ##STR2## in which X.sup.1 is N or C--R.sup.1,X.sup.2 is N or C--R.sup.9,X.sup.3 is N or C--R.sup.2,R.sup.1 is lower alkyl,R.sup.2 is hydrogen, lower alkyl, etc.,R.sup.9 is hydrogen or lower alkyl,R.sup.3 is halogen, etc.,R.sup.4 is halogen, etc.,R.sup.5 is a group of the formula: ##STR3## A is lower alkylene, and Y is O, etc.,and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods to using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Abstract: A compound of the formula: ##STR1## wherein --X.sup.3 .dbd.X.sup.2 --X.sup.1 .dbd.N-- is a group of the formula: ##STR2## R.sup.1 is hydrogen or halogen, R.sup.2 is halogen,R.sup.3 is hydrogen, nitro, amino optionally having at least one substituent or a heterocyclic group optionally having at least one substituent,R.sup.4 and R.sup.5 are each hydrogen, or halogen,R.sup.6 and R.sup.8 are each hydrogen, halogen, lower alkyl, hydroxy, lower alkylthio, amino optionally substituted with lower alkyl, or lower alkoxy optionally substituted with a substituent selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino and aryl optionally substituted with lower alkoxy,R.sup.7 is hydrogen or lower alkyl,A is lower alkylene, andQ is O or N--R.sup.9 is hydrogen or acyl,provided that R.sup.3 is not hydrogen when X.sup.1 is C--R.sup.6, in which R.sup.6 is hydrogen, andpharmaceutically acceptable salts thereof.

Abstract: The invention relates to bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.

Abstract: A novel industrial process excellent in yield and purity for preparing a compound of the formula: ##STR1## or a salt thereof, which comprises reacting a compound of the formula: ##STR2## or a salt thereof with a compound of the formula:R.sup.3 --A--OHor its reactive derivative or a salt thereof,wherein R.sup.2 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, each of which may be substituted with halogen,R.sup.

Abstract: A compound of the formula: ##STR1## or its salt is prepared by reacting a compound of the formula: ##STR2## with a compound of the formula: ##STR3## Wherein the variables are all defined in claim 1.

Abstract: The invention relates to novel bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.

Abstract: This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin- or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.

Abstract: This invention related to compounds of the formula ##STR1## wherein the radicals are as defined in the claims. The compounds are angiotensin II antagonists useful in treating hypertension, etc.

Abstract: This invention relates to new aminopiperazine derivatives having the potentiation of the cholinergic activity and represented by the general formula [I]: ##STR1## wherein R.sup.1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, each of which may be substituted with halogen,R.sup.2 is hydrogen or lower alkyl,R.sup.3 is cyclo(lower)alkyl, aryl or ar(lower)-alkyl, each of which may be substituted with halogen,A is ##STR2## or lower alkylene, and Y is ##STR3## and pharmaceutically acceptable salts thereof, to processes for the preparation thereof and to a pharmaceutical composition comprising the same.

Abstract: The invention relates to compounds of the formula ##STR1## wherein ##STR2## represents a condensed or uncondensed imidazolyl ring and the rest of the variables are as defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc..

Abstract: The invention concerns compounds of the formula ##STR1## represents a condensed or uncondensed imidazolyl ring and the rest of the variables are defined in the specification. They are angiotensin II antagonists useful for treating hypertension, etc.